• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research

Weekly Overseas Health IT Links – 26th March, 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.-----https://mhealthintelligence.com/news/55-of-telehealth-providers-frustrated-with-overblown-patient-expectations55% of Telehealth Providers Frustrated With Overblown Patient ExpectationsProviders also cited their ability to provide quality care and technical difficulties as among their top frustrations with telehealth, a new survey shows.ByAnuja VaidyaMarch 18, 202...
Source: Australian Health Information Technology - March 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection
Mol Ther Nucleic Acids. 2022 Feb 1;27:1103-1115. doi: 10.1016/j.omtn.2022.01.020. eCollection 2022 Mar 8.ABSTRACTDespite the existence of a prophylactic vaccine against hepatitis B virus (HBV), chronic hepatitis B virus (CHB) infection remains the leading cause of cirrhosis and liver cancer in developing countries. Because HBV persistence is associated with insufficient host immune responses to the infection, development of an immunomodulator as a component of therapeutic vaccination may become an important strategy for treatment CHB. In the present study, we aimed to design a novel immunomodulator with the capacity to sub...
Source: Cancer Control - March 1, 2022 Category: Cancer & Oncology Authors: Irina Ushach Ren Zhu Elen Rosler Rajendra K Pandey N Tilani S De Costa Soheil Pourshahian Qinglin Han Chris Li Leonid Beigelman Sergei M Gryaznov Theodore Yun Source Type: research

Road to elimination of HCV: Clinical challenges in HCV management
Liver Int. 2021 Dec 30. doi: 10.1111/liv.15150. Online ahead of print.ABSTRACTSince its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). With direct-acting antiviral (DAA) combination therapies such as glecaprevir/pibrentasvir and velpatasvir/sofosbuvir, 98% of patients successfully eradicate the virus, even if previous treatments failed or if resistance-associated substitutions (RASs) are present. Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often elig...
Source: Cancer Control - December 30, 2021 Category: Cancer & Oncology Authors: C Nelson Hayes Michio Imamura Junko Tanaka Kazuaki Chayama Source Type: research

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
World J Gastroenterol. 2021 Nov 21;27(43):7497-7508. doi: 10.3748/wjg.v27.i43.7497.ABSTRACTNew hepatitis B virus (HBV) infections are decreasing owing to improved antiviral therapy and increased HBV vaccination worldwide; however, the number of HBV infections remains a major cause of liver carcinogenesis. HBV triggers cytotoxic immunity to eliminate HBV-infected cells. Therefore, the HBV pathophysiology changes in persistently infected individuals depending on host immune responses and HBV DNA proliferation state. To prevent liver cirrhosis and carcinogenesis caused by HBV, it is important to treat HBV infection at an earl...
Source: World Journal of Gastroenterology : WJG - December 10, 2021 Category: Gastroenterology Authors: Miwa Kawanaka Ken Nishino Hirofumi Kawamoto Ken Haruma Source Type: research

Pages: 1  2  3  4  5  6  7